INDRAMEDCOHealthcare

Indraprastha Medical Corporation Limited

Hospital · ISIN INE681B01017 · BSE 532150 · NSE EQ · FV ₹10
Last price
₹364
+1.99%today
What this company does

Indraprastha Medical Corporation Limited operates in Hospital, part of the Healthcare sector. It booked ₹406 cr of revenue in its latest quarter (Q1 FY27) and kept 13.8% of sales as profit.

In the report:
80out of 100
Equitytale Health Score
Fortress

Healthier than 80% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 13–150 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
51

At close. Not part of the score.

Profitability & returns86

How much profit it earns on the money it employs

Balance sheet87

How much it owes, and whether earnings cover the interest

Cash quality64

Whether reported profit actually arrives as cash

Growth & consistency71

Whether sales and profit have grown, and how steadily

Valuation75

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Is this company doing well?
not investment advice
Strengths
Makes a profit
Sales up 11% vs last year
Profit up 9% vs last year
Promoters hold 51%
No promoter shares pledged
Strong 30% return on equity
Virtually debt-free
Turns profit into real cash
Watch-outs
None flagged from our data

What if I invest in INDRAMEDCO?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 15% a year, it would become
₹26.30 lakh

The slider starts at 15%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹364 +1.99%
latest close · 2026-09-17
1-year return
+389.4%
52-wk low ₹5252-wk high ₹406
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio14.9Low
LowAverageHigh
P/B ratio4.50High
Below bookModerateHigh
EV / EBITDA9.4Average
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity30.2%Strong
WeakFairStrong ▸15%
Return on capital37.2%Strong
WeakFairStrong
Net margin13.8%Decent
ThinDecentStrong
EBITDA margin21.7%Healthy
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.00Comfortable
LowModerateHigh ▸1
Interest cover46.3×Strong
RiskyOkayStrong ▸5×
Current ratio2.46Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹3,334 cr
Book value
₹81
EPS
₹6.09
latest quarter
Net debt
₹-5 cr
more cash than debt
Enterprise value
₹3,329 cr
EBITDA
₹353 cr
annualised
EBIT
₹306 cr
annualised
Operating margin
18.8%
Return on assets
22.5%
Earnings yield
6.70%
P/S
2.05
Sales / share
₹177.2
Tax rate
25.4%
Face value
₹10
Shares
9.2 cr
Working capital
₹247 cr
Current assets
₹417 cr
Current liabilities
₹170 cr
Delivery %
58.8%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.

Worth vs price · from the FY 2025 report & filings
not investment advice
Looks overpricedHigh confidence
Median of 3 models ₹224 vs market price ₹364 — price is 62% above it
Safety cushion-62.5%(target ≥ +20%)
Models span ₹177₹231, midpoint ₹224
Model ₹224
Price ₹364
Cheap sideExpensive side

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q1 FY27 (consolidated)
Revenue from Operations₹406 cr
Other Income₹8 cr
Total Income₹415 cr
Cost of Materials₹70 cr
Purchases of Stock-in-Trade₹0 cr
Employee Benefit Expense₹73 cr
Finance Costs₹2 cr
Depreciation & Amortisation₹12 cr
Other Expenses₹183 cr
Total Expenses₹340 cr
Profit before Tax₹75 cr
Tax Expense₹19 cr
Net Profit₹56 cr
Net margin on total income13.5%
Where the money goes · Q1 FY27
% of total income
Materials + stock-in-trade₹70 cr16.9%
Employee benefit expense₹73 cr17.6%
Finance costs₹2 cr0.4%
Depreciation & amortisation₹12 cr2.8%
Other expenses₹183 cr44.2%
Tax expense₹19 cr4.6%
Profit for the period₹56 cr13.5%
Total income ₹415 cradds up to ₹100 ✓
Quarterly results · consolidated (₹ cr)
MetricQ3 FY26Q4 FY26Q1 FY27
Revenue372 cr365 cr406 cr
Total income379 cr372 cr415 cr
Expenses322 cr317 cr340 cr
Profit before tax56 cr55 cr75 cr
Tax15 cr13 cr19 cr
Net profit (owners' share)41 cr42 cr56 cr
Net margin (owners' share, on revenue)11.0%11.4%13.8%
EPS (₹)4.474.556.09
YoY (latest quarter): total income +11.5% · net profit +8.5%
Balance sheet & cash flow · as of Mar 2026
Debt-free
Total assets
₹991 cr
Shareholder equity
₹740 cr
parent shareholders
Total debt
₹0 cr
Cash
₹5 cr
Cash flow · H1 FY26
Operating
₹94 cr
Investing
₹-147 cr
Financing
₹-6 cr
Peer comparison
Hospital · by market value
CompanyPriceMarket capP/E
Apollo Hospitals Enterprise Limited₹8,769₹1.26 L cr54.3
Max Healthcare Institute Limited₹1,037₹1.01 L cr78.1
Manipal Health Enterprises Limited₹722₹85,125 cr92.0
Fortis Healthcare Limited₹886₹66,897 cr62.8
Aster DM Quality Care Limited₹761₹39,412 cr613.4
Global Health Limited₹1,424₹38,273 cr60.2
Narayana Hrudayalaya Ltd.₹1,869₹38,187 cr45.8
Krishna Institute of Medical Sciences Limited₹792₹33,258 cr190.3
Dr. Agarwal's Health Care Limited₹500₹15,855 cr87.4
Same industry · latest reported numbers · not a recommendation.
Corporate actions
Dividend yield
trailing 12 months
Dividend / share (TTM)
Last dividend
₹4.5
ex 18 Sep 2025
ActionDetailEx-date
Dividend₹4.5 / share18 Sep 2025
Dividend₹4.5 / share13 Sep 2024
Dividend₹3 / share15 Sep 2023
Dividend₹2.5 / share15 Sep 2022
Dividend₹1.6 / share12 Sep 2019
Dividend₹1.5 / share12 Sep 2018
Who owns it · 2026-06-30
No pledge
Promoter
51.0%
FII / Foreign
2.8%
DII / Domestic
0.6%
Retail / others
45.6%
Smart-money activity
Bulk / block deals
short · NSE553 Sep 26
short · NSE7027 May 26
short · NSE5110 Apr 26
Stake changes
SoldHDFC Bank Limited→ 2.45% · 27.82 L4 Apr 24
SoldHDFC Bank Ltd→ 5.49% · 20.24 L28 Feb 24
BoughtHDFC Bank Limited→ 6.71% · 61.47 L1 Jul 23
What shareholders were asked to approve
4 proposals passed only on promoter votes

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Postal ballot · 20 Mar 2026
See the official result
1
To consider and approve re-appointment of Mr. Salil Singhal (DIN:00006629) as an Independent Director of the Company.
Backed by 99% of shareholders other than promotersneeded 75%
19.27 L votes for, 14,499 against · 0% of mutual funds and other big investors said no
2
To consider and approve re-appointment of Ms. Vineeta Rai (DIN:07013113) as an Independent Director of the Company.
⚑ Passed only because promoters voted yes
Backed by 29% of shareholders other than promotersneeded 75%
5.59 L votes for, 13.82 L against · 98% of mutual funds and other big investors said no
3
To consider and approve re-appointment of Ms. Madhumita Ganguli (DIN:00676830) as an Independent Director of the Company.
⚑ Passed only because promoters voted yes
Backed by 40% of shareholders other than promotersneeded 75%
7.71 L votes for, 11.71 L against · 83% of mutual funds and other big investors said no
4
To consider and approve appointment of Mr. Harsh Pati Singhania (DIN:00086742) as an Independent Director of the Company.
Backed by 93% of shareholders other than promotersneeded 75%
18.04 L votes for, 1.37 L against · 9% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 14 named members
owning 51.0% between them · as of 2026-06-30
PRESIDENT OF INDIA26.00%
APOLLO HOSPITALS ENTERPRISES LIMITED22.02%
WEDGEWOOD HOLDINGS LIMITED1.61%
PCR INVESTMENT LIMITED0.42%
PRATAP C REDDY0.26%
PREETHA REDDY0.22%
SUCHARITHA P REDDY0.18%
SUNEETA REDDY0.15%

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.